Rifaximin Versus Lactulose in Renal Failure

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00748904

Enrollment

Registered

2008-09-09

Start date

2008-06-30

Completion date

2009-07-31

Last updated

2022-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Renal Failure

Keywords

cirrhosis of liver and progressive renal failure

Brief summary

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

Interventions

DRUGRifaximin

400 mg orally

DRUGLactulose

20 grams titrate to 2-3 bowel movements in one day

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* cirrhosis of liver of any etiology * progressive renal failure * stage 0-2 hepatic encephalopathy

Exclusion criteria

* pregnant women

Design outcomes

Primary

Measure	Time frame
slower progression to severe hepatic encephalopathy, stage 3 or 4	during hospitalization

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026